Tafamidis ATTR Cm denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tafamidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Tafamidis-Attr-Cm as Duplicate Therapy — and Why This Is Typically Incorrect

A "duplicate therapy" denial for tafamidis in the context of ATTR cardiomyopathy (ATTR-CM) usually means UHC's system has identified another agent in the patient's medication profile that it has categorized as serving the same therapeutic purpose. This classification is almost always a system-level error, because tafamidis has a specific, disease-modifying mechanism — transthyretin stabilization — that is distinct from supportive cardiac medications commonly prescribed alongside it (such as diuretics, beta-blockers, or other heart failure agents). Those agents manage symptoms; tafamidis targets the underlying protein misfolding process.

The appeal strategy is to demonstrate that no true therapeutic duplicate exists: the other drug(s) in the patient's profile have a different mechanism, a different FDA-indicated use, or are treating a different aspect of the disease.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Duplicate-therapy denials are adverse benefit determinations subject to full internal appeal rights. Request from UHC the specific drug(s) it identified as duplicates and the clinical rationale.
• External review: After an adverse internal decision, you may request IRO review. Federal law provides approximately four months from the adverse determination. Expedited review is available for urgent situations.

## Documentation to Gather

1. Mechanism-of-action comparison — your prescriber should write a letter explaining tafamidis's specific mechanism (TTR stabilization) and how it differs from every other agent UHC identified as a duplicate. 2. FDA label for each flagged drug — attach the FDA-approved prescribing information for tafamidis and for the alleged duplicate(s), with the approved indications highlighted. If the indications differ, the duplicate classification fails. 3. Prescriber medical-necessity letter — state that each medication in the patient's regimen serves a distinct and non-overlapping therapeutic purpose, and that removing tafamidis would leave the underlying disease process unaddressed. 4. Current medication list with indications — provide the full medication list with the clinical reason for each drug, showing no true overlap. 5. Applicable cardiology guideline reference — ask the prescriber to note that the relevant ACC/AHA or applicable guideline organization supports combination therapy for ATTR-CM patients.

## Criteria-Mapping Structure

| UHC's Alleged Duplicate | Why It Is Not a Duplicate | |---|---| | [Drug identified by UHC] | Different mechanism: [describe]; Different FDA indication: [cite label] | | Tafamidis role | Targets TTR stabilization; no other approved agent in profile does this |

This denial typically reverses quickly once the prescriber's letter and the two FDA labels are submitted side by side.